BAYRY
Bayer Aktiengesellschaft
OTC Markets OTCQXUSDEQUITY
DELAYED
Last price
14.06
▼ 0.06 (0.42%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
13.94
Prev close
14.12
Day high
14.06
Day low
13.90
Volume
22.31K
Market cap
—
P/E (TTM)
—
52W range
7.48 – 15.23
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+1.59%
+3.0%
1M
+7.08%
+3.4%
3M
+24.65%
+21.5%
6M
+9.76%
-1.3%
YTD
+29.94%
+17.7%
1Y
+73.37%
+53.4%
3Y
+1.52%
-72.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $45.58B | $46.61B | $47.64B | $50.74B | -2.2% |
| Operating revenue | $45.58B | $46.61B | $47.64B | $50.74B | -2.2% |
| Cost of revenue | $18.80B | $21.27B | $19.75B | $19.87B | -11.6% |
| Gross profit | $26.78B | $25.34B | $27.89B | $30.87B | +5.7% |
| Research & development | $5.77B | $6.21B | $5.37B | $6.57B | -7.1% |
| Selling, general & admin | $14.71B | $15.94B | $14.94B | $16.92B | -7.7% |
| Total operating expense | $20.64B | $22.01B | $19.85B | $23.54B | -6.2% |
| Operating income | $6.14B | $3.33B | $8.04B | $7.33B | +84.5% |
| Net interest income | -$1.86B | -$1.90B | -$1.61B | -$1.82B | +2.1% |
| Pre-tax income | -$3.13B | -$2.33B | -$1.62B | $4.67B | -34.1% |
| Tax provision | $466.00M | $212.00M | $1.32B | $504.00M | +119.8% |
| Net income | -$3.62B | -$2.55B | -$2.94B | $4.15B | -41.8% |
| Net income to common | -$3.62B | -$2.55B | -$2.94B | $4.15B | -41.8% |
| Basic EPS | -0.92 | -0.65 | -0.75 | 1.06 | -41.5% |
| Diluted EPS | -0.92 | -0.65 | -0.75 | 1.06 | -41.5% |
| EBIT | -$864.00M | $24.00M | $426.00M | $6.53B | -3,700.0% |
| EBITDA | $1.92B | $8.81B | $10.45B | $13.03B | -78.2% |
| Basic shares | 3.93B | 3.93B | 3.93B | 3.93B | 0.0% |
| Diluted shares | 3.93B | 3.93B | 3.93B | 3.93B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.67B | $6.19B | $5.91B | $5.17B | +7.8% |
| Cash & short-term investments | $7.86B | $8.09B | $10.59B | $10.15B | -2.9% |
| Accounts receivable | $9.08B | $8.97B | $9.34B | $10.31B | +1.2% |
| Inventory | $12.34B | $13.40B | $13.93B | $13.60B | -8.0% |
| Total current assets | $32.91B | $34.44B | $37.56B | $37.76B | -4.5% |
| Property, plant & equipment | $12.65B | $13.46B | $13.32B | $13.67B | -6.0% |
| Goodwill & intangibles | $48.68B | $52.13B | $55.66B | $63.83B | -6.6% |
| Total assets | $104.54B | $110.85B | $116.26B | $124.88B | -5.7% |
| Total current liabilities | $32.59B | $28.95B | $29.46B | $35.08B | +12.5% |
| Current debt | $4.39B | $4.90B | $4.41B | $7.26B | -10.4% |
| Long-term debt | $30.78B | $34.55B | $37.23B | $32.83B | -10.9% |
| Total debt | $36.45B | $40.70B | $42.87B | $41.32B | -10.4% |
| Total liabilities | $78.48B | $78.81B | $83.18B | $85.95B | -0.4% |
| Shareholder equity | $25.95B | $31.91B | $32.93B | $38.77B | -18.7% |
| Working capital | $326.00M | $5.49B | $8.10B | $2.68B | -94.1% |
| Net tangible assets | -$22.74B | -$20.22B | -$22.73B | -$25.06B | -12.4% |
| Shares issued | 982.42M | 982.42M | 982.42M | 982.42M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$3.60B | -$2.55B | -$2.94B | $4.17B | -41.2% |
| Depreciation & amortisation | $2.79B | $8.78B | $10.02B | $6.50B | -68.3% |
| Change in working capital | $5.93B | $85.00M | -$4.07B | -$2.70B | +6,881.2% |
| Operating cash flow | $5.93B | $7.37B | $5.12B | $7.09B | -19.5% |
| Capital expenditure | -$2.49B | -$2.78B | -$2.75B | -$2.95B | +10.5% |
| Investing cash flow | -$1.27B | $164.00M | -$3.52B | -$2.38B | -874.4% |
| Share buybacks | -$14.00M | -$16.00M | -$24.00M | -$25.00M | +12.5% |
| Dividends paid | -$127.00M | -$131.00M | -$2.38B | -$1.99B | +3.1% |
| Financing cash flow | -$3.88B | -$7.18B | -$679.00M | -$4.22B | +45.9% |
| Free cash flow | $3.44B | $4.59B | $2.37B | $4.14B | -25.0% |
| End cash position | $6.67B | $6.19B | $5.91B | $5.17B | +7.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $10.87B | $13.40B | $11.44B | $9.66B | $10.74B | — | -18.9% |
| Operating revenue | $10.87B | $13.40B | $11.44B | $9.66B | $10.74B | — | -18.9% |
| Cost of revenue | $4.54B | $5.23B | $4.50B | $4.31B | $4.36B | — | -13.2% |
| Gross profit | $6.33B | $8.17B | $6.94B | $5.35B | $6.38B | — | -22.5% |
| Research & development | $1.52B | $1.42B | $1.41B | $1.50B | $1.41B | — | +7.0% |
| Selling, general & admin | $3.96B | $3.70B | $4.05B | $3.40B | $3.54B | — | +7.2% |
| Total operating expense | $5.50B | $4.64B | $2.59B | $5.90B | $6.36B | — | +18.5% |
| Operating income | $827.00M | $3.53B | $4.34B | -$543.00M | $13.00M | — | -76.6% |
| Net interest income | -$424.00M | -$516.00M | -$319.00M | -$632.00M | -$401.00M | — | +17.8% |
| Pre-tax income | $321.00M | $2.99B | -$3.37B | -$1.16B | -$426.00M | — | -89.3% |
| Tax provision | $92.00M | $222.00M | $378.00M | -$202.00M | -$236.00M | — | -58.6% |
| Net income | $219.00M | $2.76B | -$3.76B | -$963.00M | -$199.00M | — | -92.1% |
| Net income to common | $219.00M | $2.76B | -$3.76B | -$963.00M | -$199.00M | — | -92.1% |
| Basic EPS | 0.06 | 0.70 | — | -0.25 | -0.05 | 0.33 | -91.8% |
| Diluted EPS | 0.06 | 0.70 | — | -0.25 | -0.05 | 0.33 | -91.8% |
| EBIT | $755.00M | $3.46B | -$2.95B | -$399.00M | -$36.00M | — | -78.2% |
| EBITDA | $1.91B | $4.72B | -$2.61B | $606.00M | $236.00M | — | -59.4% |
| Basic shares | 3.93B | 3.93B | — | 3.93B | 3.93B | 3.93B | 0.0% |
| Diluted shares | 3.93B | 3.93B | — | 3.93B | 3.93B | 3.93B | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.29B | $5.73B | $6.67B | $5.90B | $4.56B | — | -25.1% |
| Cash & short-term investments | $5.08B | $6.66B | $7.86B | $7.24B | $5.50B | — | -23.7% |
| Accounts receivable | $12.88B | $12.91B | $9.08B | $9.99B | $12.88B | — | -0.2% |
| Inventory | $11.97B | $12.01B | $12.34B | $12.33B | $12.11B | — | -0.4% |
| Total current assets | $33.64B | $35.30B | $32.91B | $32.88B | $33.75B | — | -4.7% |
| Property, plant & equipment | $12.76B | $12.73B | $12.65B | $12.48B | $12.47B | — | +0.2% |
| Goodwill & intangibles | $49.36B | $48.85B | $48.68B | $48.05B | $48.31B | — | +1.0% |
| Total assets | $107.28B | $107.94B | $104.54B | $104.21B | $105.24B | — | -0.6% |
| Total current liabilities | $32.27B | $33.46B | $32.59B | $28.96B | $29.78B | — | -3.6% |
| Current debt | — | — | $4.39B | — | — | $4.90B | — |
| Long-term debt | — | — | $30.78B | — | — | $34.55B | — |
| Total debt | — | — | $36.45B | — | — | $40.70B | — |
| Total liabilities | $77.58B | $78.98B | $78.48B | $74.51B | $74.74B | — | -1.8% |
| Shareholder equity | $29.58B | $28.84B | $25.95B | $29.58B | $30.37B | — | +2.6% |
| Working capital | $1.37B | $1.84B | $326.00M | $3.92B | $3.97B | — | -25.4% |
| Net tangible assets | -$19.77B | -$20.01B | -$22.74B | -$18.47B | -$17.94B | — | +1.2% |
| Shares issued | 982.42M | 982.42M | 982.42M | 982.42M | 982.42M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $229.00M | $2.77B | -$3.75B | -$959.00M | -$190.00M | — | -91.7% |
| Depreciation & amortisation | $1.16B | $1.25B | $334.00M | $1.00B | $272.00M | — | -7.7% |
| Change in working capital | -$951.00M | -$6.16B | $7.38B | $1.43B | $1.31B | — | +84.5% |
| Operating cash flow | $690.00M | -$1.79B | $4.20B | $1.69B | $1.06B | — | +138.5% |
| Capital expenditure | -$660.00M | -$411.00M | -$798.00M | -$836.00M | -$465.00M | — | -60.6% |
| Investing cash flow | -$707.00M | $280.00M | -$518.00M | -$1.07B | $154.00M | — | -352.5% |
| Dividends paid | -$112.00M | — | -$11.00M | -$8.00M | -$108.00M | -$13.00M | — |
| Financing cash flow | -$1.48B | $528.00M | -$2.89B | $730.00M | -$482.00M | — | -379.7% |
| Free cash flow | $30.00M | -$2.21B | $3.40B | $849.00M | $593.00M | — | +101.4% |
| End cash position | $4.29B | $5.73B | $6.67B | $5.90B | $4.56B | — | -25.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.06
+0.02% from price
SMA 20
13.98
+0.61% from price
SMA 50
13.31
+5.62% from price
SMA 100
12.20
+15.22% from price
SMA 200
11.61
+21.06% from price
EMA 12
14.05
+0.10% from price
EMA 26
13.83
+1.63% from price
EMA 50
13.34
+5.42% from price
RSI (14)
55.0
Neutral
MACD (12,26,9)
0.21
Hist -0.04
ATR (14)
0.29
2.07% of price
Realised vol 30D
25.3%
Annualised
Bollinger upper
14.55
20, 2σ
Bollinger lower
13.40
20, 2σ
50 / 200 cross
Golden
13.31 vs 11.61
Trend bias
Above 200
+21.06%
Risk profile
Beta vs SPY
0.64
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
25.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-31.4%
Peak to trough
Max drawdown 5Y
-73.7%
Peak to trough
ATR 14
0.29
2.07% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
MustGrow Biologics Secures First Milestone Payment from Bayer
MT Newswires · 2d ago
MustGrow Receives First Milestone Payment from Bayer AG
TMX Newsfile · 2d ago
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
Zacks · 2d ago
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
Business Wire · 3d ago
Bayer (XTRA:BAYN) Stock May Be Undervalued As Canada Drug Approval Expands
Simply Wall St. · 3d ago
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Zacks · 3d ago
Is Bayer (XTRA:BAYN) Below Fair Value After Health Canada Expanded LYNKUET Approval?
Simply Wall St. · 4d ago
EyePoint’s Duravyu falls short to Eylea in Phase III trial
Clinical Trials Arena · 4d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.